Research Report on China's Ceftriaxone Export 2023-2032
Ceftriaxone is an antibiotic that can be used to treat a wide range of bacterial infections such as Gram-positive and Gram-negative bacteria, and is one of the most effective and safest drugs required by public health systems. Ceftriaxone has a wide range of clinical treatments and is currently one of the major antibiotic classes worldwide. The increased pressure on global healthcare systems as more unknown and resistant bacteria emerge is driving the growth in demand for ceftriaxone.
China is one of the major global producers of ceftriaxone raw materials and exports a large amount of ceftriaxone every year. According to CRI analysis, in 2021, China exported 3,136.81 tons of ceftriaxone, up 23.17% year-on-year, with an export value of US$241 million, up 21.68% year-on-year.
In 2022, China's ceftriaxone exports declined due to the adverse impact of COVID-19 on the operations and logistics of the Chinese pharmaceutical industry. From January to November 2022, China exported 2400.50 tons of ceftriaxone, down 16.43% year-on-year, with an export value of US$229 million, up 4.91% year-on-year.
In 2021, China exported ceftriaxone to more than fifty countries and regions worldwide. CRI analysis shows that India, Russian Federation, Pakistan, Belarus and Germany are the main export destinations of ceftriaxone in China by export volume. Among them, India is the largest destination for China's ceftriaxone exports. In 2021, China exported 1,794.55 tons of ceftriaxone to India, accounting for 57.21% of the total ceftriaxone exports in that year, with an export value of US$124 million, accounting for 51.33% of the total export value.
China is the world's largest antibiotic producer. CRI expects the global ceftriaxone market size to continue to expand during 2023-2032, which will help boost China's ceftriaxone exports.
Topics covered:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook